Navigation Links
Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting
Date:5/7/2010

BALTIMORE, May 7 /PRNewswire/ -- A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.  These data will be presented during a poster session today at the 29th Annual Scientific Meeting of the American Pain Society (APS), and are supported by PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and its research affiliates, Ortho-McNeil-Janssen Scientific Affairs, L.L.C. (OMJSA) and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), as well as Grunenthal GmbH.

This post-hoc analysis of the original Phase 3 study evaluated the safety profile of tapentadol IR (n=158, either 50 or 100 mg dosed every four to six hours as needed) over a 90-day period among elderly patients (greater than or equal to 65 years of age).  The study also evaluated an oxycodone IR active comparator group (n=45, either 10 or 15 mg dosed every four to six hours as needed).

The analysis demonstrated that tapentadol IR was associated with lower incidences of specific gastrointestinal side effects versus oxycodone IR (46.8% vs. 68.9%, respectively) as well as lower incidences of study discontinuation due to gastrointestinal side effects versus oxycodone IR (15.8% vs. 24.4%, respectively). No significant between-age group differences in efficacy were observed for patients in the tapentadol IR group (P = 0.521 for patients less than 65 vs. patients greater than or equal to 65 years of age) or the oxycodone IR group (P = 0.987 for patients less than 65 vs. patients greater than or equal to 65 years of age).


'/>"/>
SOURCE PriCara,(R) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
2. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
5. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
6. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
7. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
8. New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
9. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
10. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
11. Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- Today leading ... all new data ranking Pharmaceutical web sites for usability, ... Sciences, User Experience Cloud platform, which compares how people ... on the web. The top three performers ... convert people overall. The bottom performers have usability problems, ...
(Date:6/19/2013)... 19, 2013 Today MedeAnalytics, a leading ... next-generation of its Employer Group and Individual ... to provide their employer groups an intuitive and ... and prescription drug claims, network utilization, and overall ... ) "Employer Group and Individual ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... Bristol-Myers Squibb, Company and Gilead Sciences, ... -, PRINCETON, N.J. and FOSTER CITY, Calif., ... BMY ) and Gilead Sciences, Inc.,(Nasdaq: GILD ... ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300,mg) ...
... to Compare Genous vs. Drug-Eluting and Bare ... ... Enrollment in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered ... in April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and ...
Cached Medicine Technology:Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2
(Date:6/19/2013)... LOS ANGELES (June 19, 2013) In what is ... with the most common form of hereditary dystonia ... experts in deep brain stimulation report good success ... director of the Movement Disorders Program at Cedars-Sinai Medical ... chief of the Division of Neurosurgery at Beth Israel ...
(Date:6/19/2013)... of three important studies have been published in the ... the Congress of Neurological Surgeons . The ... , a part of Wolters Kluwer Health . ... artificial neural networks (ANNs) may improve the ability to ... study in the June Neurosurgery supports increased ...
(Date:6/19/2013)... Children had half as many emergency department ... hours on five or more days a week, according ... Mott Children,s Hospital and Johns Hopkins University. , The ... The Journal of Pediatrics and will be presented ... are an important step in understanding where primary care ...
(Date:6/19/2013)... Spanish . ... goes by the name of the 10/90 gap: only 10 ... that accounted for 90 per cent of the global disease ... for Neglected Diseases initiative (DNDi) came into being in 2003. ... granted the BBVA Foundation Frontiers of Knowledge Award in the ...
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
Breaking Medicine News(10 mins):Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Why are some college students more likely to 'hook up'? 2
... many biological processes also may play a role in memory, ... California and the National Institute on Aging at the National ... the Journal of Neuroscience, agree with research by ... Both studies found that mice lacking the protein SIRT1 exhibited ...
... in specific brain regions in female patients with irritable bowel ... the abdomen, along with diarrhea, constipation or both. ... University, the study appears in the July issue of the ... that IBS is associated with both decreases and increases in ...
... HealthDay Reporter , WEDNESDAY, July 21 (HealthDay News) ... be candidates for vaginal birth in future pregnancies, say ... Gynecologists. "These guidelines emphasize again that a trial ... most women," said one of the authors of the ...
... 2010 (Oakland, Calif.) A total joint replacement registry ... patient safety, quality of care, cost-effectiveness and research, according ... editions of Clinical Orthopedics and Related Research , ... Surgeons. Kaiser Permanente,s Total Joint Replacement Registry ...
... Against the backdrop of some of the globe,s fastest ... a report launched today at the XVIII International AIDS ... a new model for scaling up treatment and prevention ... The report, "Prevention and Treatment of HIV/AIDS amongst Drug ...
... July 22, 2010 -- Child abuse is a serious problem ... United States alone. The American Academy of Pediatrics and ... abuse into four categories including neglect, physical abuse, sexual abuse, ... includes the abusive use of drugs on children. A ...
Cached Medicine News:Health News:SIRT1 gene important for memory 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 3Health News:Vaginal Delivery May Be OK After C-Section 2Health News:Vaginal Delivery May Be OK After C-Section 3Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 2Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 3Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 4Health News:The malicious use of pharmaceuticals: An under-recognized form of child abuse 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Medicine Products: